Aurobindo Pharma to acquire balance 49 percent stake in GLS Pharma for Rs 22.5 crores

Published On 2024-09-19 11:16 GMT   |   Update On 2024-09-19 11:17 GMT
Advertisement

Aurobindo Pharma has announced that the Company has entered into a binding agreement with GLS Pharma Limited, a subsidiary of the Company (GLS) and its promoters for the acquisition of balance 5,90,361 equity shares of Rs 10/- each (49% of GLS) for a purchase consideration of Rs 22.5 crores.

The shares are being acquired at a price of INR 381.12 per share.

According to a BSE filing, the Company had acquired 51% shares of GLS Pharma from Mr. Suresh Pathak and his family members, on June 17, 2022, and is now acquiring the balance 49% equity shares of GLS. This acquisition is undertaken to hold the entire ownership of GLS by the Company. GLS will become a wholly owned subsidiary of the Company post the acquisition.

Advertisement
GLS Pharma Limited is a pharmaceutical company engaged in the business of Oncology products which include orals and injectables used in chemotherapy for solid malignancies, chemotherapy for hematological malignancies and chemo supportive products (the "Business").

GLS was incorporated on 01/09/2004 and initiated manufacturing in the year 2015. It had a total sales of INR 32.99 crores during FY 23-24, INR 36.08 crores during FY 22-23 and INR 25.84 crores during FY 21-22.

The completion of the acquisition is estimated before December 31, 2024. 

Read also: Aurobindo Pharma step-down arm AP facility gets product approval from USFDA

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 29 manufacturing and packaging facilities that are approved by regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News